Member Article

Manchester-based law firm Slater Heelis closes $1.75m round of investment for drug company

Manchester-based law firm Slater Heelis has advised Macclesfield-based pharmaceutical developer, Blueberry Therapeutics, helping the company secure $1.75m of funding.

The capital will be used to progress two of the drug company’s programmes to clinical trial.

Blueberry Therapeutics is a pharmaceutical company that uses nanotechnology-based drug delivery platforms to exploit both small molecule and biologic approaches to the creation of new medicines.

Partner at Slater Heelis and key adviser on the investment, Simon Wallwork, said: “Blueberry Therapeutics continues to develop an impressive range of pharmaceutical solutions and I’m confident that this funding will enable it to create new products that will lead to positive outcomes for patients and treatment providers.”

Blueberry Therapeutics’ CEO, Dr John Ridden, said: “Securing this investment is an extremely significant stepping stone in our journey to deliver new therapies to patients suffering from serious bacterial and fungal infections.”

Slater Heelis is a leading Manchester-based law firm providing progressive legal advice to commercial, not-for-profit and private clients across a number of practice disciplines.

This was posted in Bdaily's Members' News section by Sophia Taha .